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Abstract Withahandheldpeakinspiratory flow (PIF)meter (In-CheckDIALs), theinternalresistanceoftheDiskuss
(DKR) and theTurbuhalers (THR) can be simulated bymeans of calibrated resistances.This study investigatedwhether
patientswith asthmaorchronicobstructivepulmonarydisease couldgenerate a PIF whichis optimal for theDiskus (DK)
(30 l/min) and theTurbuhaler (TH) (60 l/min).Peakexpiratory flow (PEF) andmaximal inspiratory pressure (MIP) were
also assessed. All 50 patients (30 males, mean age 56.9) achieved the required flow of 30 l/minwith the DKR, while six
patients (five females) could not generate the optimal flow of 60 l/min via theTHR. Analysis showed that MIP was an
independent predictor of an adequate PIF throughtheTHR.During the study, eightpatientswere treated for an exacer-
bation of which four could not generate an adequate PIF via theTHR. Analysis showed that the female gender and an
exacerbation appeared to be independent predictors of the inability to generate an adequate PIF via theTHR.Twelve
per cent of patients (25% of females) could not generate the optimal inspiratory flow via the THR.When in doubt
whether the patient can generate an adequate inspiration, measurement with the In-Check DIALs is recommended.
r 2002 Publishedby Elsevier Science Ltd.
Available online athttp://www.sciencedirect.com
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In the treatment of asthma and chronic obstructive pul-
monary disease (COPD), inhaledmedication plays an im-
portant role, although room for improvement in
inhalation technique has been demonstrated convin-
cingly in the last few decades (1^6). InThe Netherlands,
as in some other European countries, dry powder inha-
lers (DPIs) are increasingly replacingmetered dose inha-
lers (MDIs). For a DPI, the inhalation has to be deep and
forceful to disperse themedication adequately (7). An in-
spiratory £ow of 30^60 l/min, depending upon the type
of inhaler, is necessary to guarantee an optimal lung de-
position of themedication (8).The characteristics of the
various DPIs depend in part on the internal air£owresis-
tance, which has consequences for the optimal inspira-
tory £ow.Therefore, it is important to assess whether a
patient can generate the required £ow for the inhaler
that is being considered. It has been shown that patients
with a clearly disturbed ventilatory capacity and youngReceived1October 2001, accepted in revised form 2 January 2002.
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E-mail: vdpalen@euronet.nlchildren have a lower inspiratory £ow (9). In these pa-
tients, it is important to prescribe an inhaler where a
low £owguarantees an adequate lungdeposition. Studies
investigating peak inspiratory £ow (PIF) have been per-
formed for theTurbuhalers (TH), where the devicewas
placed in series with a £ow meter. Obviously, although
valid, this is not possible for themajority of doctors pre-
scribing medication. Clement Clerke International Ltd
has recentlydeveloped a hand-heldpeak inspiratory £ow
(PIF) meter (In-Check DIALs, Fig.1), that canmimic the
internal resistance of a number of inhalers via calibrated
resistances.Each setting on the dial corresponds to a dif-
ferent type of inhaler (e.g. the DiskusF GlaxoSmithK-
line, TurbuhalerF AstraZeneca, ClickhalerF Medeva
Pharma Ltd, Easibreathe F Norton Healthcare and
GlaxoSmithKline and the Autohaler F3M Healthcare
Ltd.). In this way, the resistance of the original inhaler
can be simulated, and it is possible to check whether
the patient can generate an adequate inspiratory £ow
for an optimal inhalation of the medication.The internal
resistance of theTH (83Pa0.5 s/l) is higher than the inter-
nal resistance of the Diskuss (DK) (63Pa0.5 s/l).
For the DK, an inspiratory £ow of 30 l/min is enough
for optimal deposition of themedication in the lungs and
lung deposition remains constant until a £ow of 90 l/min.
FIG. 1. In-Check DIALs.
TABLE 1. Baseline demographics
Patientcharacteristics
Patients: n 50
Sex: n (%)
Male 30 (60%)
Female 20 (40%)
Mean age, years (7SD) 56.9 (16.5)
Patientswith asthma: n (%) 27 (54%)
Patientswith COPD: n (%) 23 (46%)
Duration of asthma: meanyears (7SD) 12.0 (11.0)
Duration of COPD: meanyears (7SD) 13.0 (15.5)
Abbreviations: SD, standard deviation; COPD, chronic
obstructive pulmonarydisease.
286 RESPIRATORYMEDICINEFor theTH, a £ow of 30 l/minwill ensure clinical e⁄cacy
(10,11), but 60 l/min should be considered optimal, be-
cause of the steep increase in lung deposition with in-
creasing inspiratory £ow (8,12^14).The goal of this pilot
study was to investigate which PIF’s patients generate
with maximal e¡ort, through two di¡erent resistances,
representing the DK and the TH. Also, patients who
could generate an optimal PIF were characterised by
means of age, gender and various lung function para-
meters.
METHODS
Fifty patients of the outpatient clinic of pulmonarymed-
icine of the Medisch SpectrumTwente at Enschede,The
Netherlands, who inhaled medication for asthma or
COPD, were asked to participate in the study. All pa-
tients gave written informed consent and the study was
approved by the local ethics committee. PIF was mea-
sured using the In-check DIALs (Fig.1). Patients inhaled
through the device set for both the optimal TH-resis-
tance (THR; 60 l/min) and DK-resistance (DKR; 30 l/
min).The resistancewas randomised and the highest va-
lue of three attempts was recorded with both theTHR
and DKR. Standard spirometry (Sensormedicss Pulm-
onet III spirometer) was also performed including FEV1
and vital capacity (VC), and peak expiratory £ow (PEF)
was assessed. The highest value of three attempts was
recorded for all parameters. Maximal inspiratory pres-
sure (MIP), a measure of inspiratory muscle force was
also measured according to the methodology of Black
and Hyatt (15) by means of a pressure transducer (Vali-
dynes CD 223).
The number of patients who could not achieve the
30 l/min with the DKR and 30 l/min (minimum) and 60 l/
min (optimum)with theTHRwas calculated.To stimulate
the patients all manoeuvres were executed under the
supervision of a well-trained lung function assistant. Pa-
tients were asked to withold short-acting b2-agonists
and anticholinergics for 4h prior to each lung function
measurement and long-acting b2-agonists for 8h.Statisticalmethods
The relationship between lung function parameters and
PIF was studied by means of correlation andmultiple lo-
gistic regression analysis. In this last analysis, variables,
which were independent predictors of an inadequate
PIF, were studied.Di¡erences in continuous variables be-
tween both resistances were assessed by the t-test with
95% con¢dence intervals (95% CI), or in case of a non-
Normal distribution, with Wilcoxon’s rank sum test.
Correlations were calculated via Pearson’s correlation
coe⁄cient. Di¡erences in percentage of patients that
could not generate the required £ows were analysed
with the chi-squared test, or, in case of low expected
numbers, with Fisher’s exact test.
RESULTS
Fifty patients (30 males) with a mean age of 56.9 years
were included in the study.Twenty-seven (54%) had asth-
ma and 23 (46%) had COPD (Table1).Themean duration
of their disease was 12.3 years (SD 13.0). Lung function
characteristics are presented in Table 2. The mean PIF
through theDKRwas118 l/min (SD 29.7), whichwas signif-
icantly higher than the 88 l/min (SD 21.6) through theTHR
(Po0.001; 95% CI 26.7^32.7). With both the DKR and
THR all patients achieved the requiredminimum £ow of
30 l/min. However, with theTHR 6 patients (12%) could
not generate the optimal £ow of 60 l/min.The di¡erence
between DKR and THR in percentage of patients not
able to generate an optimal £ow was statistically signi¢-
cant (P=0.03).
RELATIONSHIPBETWEENPIFAND
LUNGFUNCTIONPARAMETERS
PIF correlated very well with MIP, PEF and VC and rea-
sonably well with FEV1 (all Po0.001). The correlation
TABLE 2. Baseline lung function characteristics
Mean (SD) Range
FEV1(l) 2.22 (0.93) 0.6^4.9
FEV1%predicted 72.4 (22.8) 26^125
MIP (kPa) 8.4 (3.2) 2.6^19.4
PEF (l/min) 368 (125) 100^680
VC (l) 3.66 (1.23) 1.5^6.7
Abbreviations: SD, standarddeviation;FEV1, forced expiratory volumein1s;MIP, meaninspiratorypressure;PEF, peakexpira-
tory force;VC, vital capacity; l, litres.
TABLE 3. Pearson correlations
MIP PEF VC FEV1 FEV1%pred
PIF throughTH 0.868 0.743 0.711 0.592 0.243
PIF through DK 0.832 0.820 0.779 0.660 0.307
Abbreviations: PIF, peak inspiratory £ow; FEV1, forced expiratory volume in 1s; MIP, mean inspiratory pressure; PEF, peak
expiratory force;VC, vital capacity;TH,Turbuhaler;DK,Diskus.
FIG. 2. Mean PIF (l/min) for patients inhaling through the In-
Check DIALs calibrated for the optimal DKand THR (bars re-
present SD).
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predicted) was weak. The correlation coe⁄cients are
presented inTable 3. In a multivariate logistic regression
analysis with the above-mentioned lung function para-
meters, only MIP was an independent predictor of a PIF
o60 l/min through theTHR.ThemeanMIP of the six pa-
tients not able to generate 60 l/min via theTHRwas 3.98
(SD 1.14), while for the others this was 8.99 (SD 2.9)
(Po0.001; 95%CI 2.6^7.4).Because all patients generated
a PIF430 l/min, no othermultivariate logistic regression
analyses could be performed.
RELATIONSHIPBETWEENPIFAND
PATIENTCHARACTERISTICS
For the 30 males, the mean PIF through the DKR and
THR was 130 and 97 l/min (Po0.001; 95% CI 29.7^36.3),
respectively.For the 20 females, this was101and 76 l/min
(Po0.001; 95% CI19.5^30.0), respectively (Fig. 2).The dif-
ference between males and females was signi¢cant both
for the DKR (29.3 l/min; 95% CI 14.2^ Po0.001) and the
THR (21.1l/min; 95% CI 10.0^32.2; Po0.001). With both
the DKR and theTHR, everybody could generate430 l/
min, whilewith theTHRonemale (3.3%) and ¢ve females
(25%) achieved a PIFo60 l/min. For the females, the dif-
ference betweenTHR andDKRwas signi¢cant (Po0.05).
Two asthma patients could not generate 60 l/min with
theTHR, compared to four patients with COPD.This dif-
ferencewas not signi¢cant.For patients with COPD, the
mean PIF for both the DKR (107 l/min) and theTHR (81l/min) was signi¢cantly lower than for asthma patients
(128 and 95 l/min for the DKR and THR, respectively;
Po0.011and 0.021).
Eight patients (16%) were treated for an exacerbation
at the time of the study, of which three patients (6%)
were admitted. All patients with an exacerbation gener-
ated a PIF 4 30 l/min via both resistances. Four of the
eight patients (50%) with an exacerbation could not gen-
erate a PIF of 60 l/min via theTHR.Of those without an
288 RESPIRATORYMEDICINEexacerbation two (5%) could not produce this £ow
(Po0.004). Of the 21 patients (42%) who had not used
short- or long-acting b2-agonists prior to the measure-
ments, everybody generated a PIF 430 l/min through
both resistances, and 460 l/min though the THR. Of
the 29 patients (58%) who had been using a b2-agonist,
six did not achieve a PIF of 60 l/min with theTHR. In a
multivariate logistic regression analysis, the female gen-
der and experiencing an exacerbationwere independent
predictors of the inability to generate 60 l/min via the
THR.Because all patients generated a PIF430 l/min, no
other multivariate logistic regression analyses could be
performed.
DISCUSSION
There are numerous inhalation devices available and the
decision of which is the most appropriate for each pa-
tient is di⁄cult tomake for the prescriber.The In-Check
DIALs has been recently introduced and studies have
highlighted the potential of this meter to identify the in-
spiratory e¡orts of all types of patients, including chil-
dren and patients with COPD, using a selection of DPIs
(16^19).
In this study, using the In-check DIALs, all patients
could achieve inspiratory £ows430 l/min with both in-
haler-resistances, thus ensuring at least a clinical e¡ect.
However, 12percent of all patients (25% of all females)
could not generate the optimal inspiratory £ow of 60 l/
min via theTHR.These weremainly patients with an ex-
acerbation, patientswith a lowMIP and females.The fact
that MIP showed the highest correlation with PIF, indi-
cates that inspiratory muscle force is probably the most
important predictor of an adequate inspiratory £ow.
This would also explain why it concerns mainly females
and patients with an exacerbation. For the last category
this could be due to fatigue of the respiratory muscles
and the concomitant reduction inmuscle strength.
The six patients in this study who could not generate
60 l/min with theTHR, had all used b2-agonists prior to
the study. This is probable ‘‘confounding by indication’’;
this means that patients who were well would not have
used this class of medication.Of the eight patients trea-
ted for anexacerbation, allusingbronchodilatingmedica-
tion, 50% could not generate the optimal inspiratory
£ow via theTHR. This is important because during ex-
acerbations bronchodilating medication is essential. It is
likely, that in patients with an exacerbation, who all had
used bronchodilating medication, the PIF values would
have been even lower before bronchodilation (9). How-
ever, it has been convincingly shown, that even at subop-
timal £ows of 30 l/min, theTH still provides a reasonable
clinical e¡ect.
Various studies show that the lung deposition of the
inhaledmedication with the DK is optimal and constantfrom 30 to 90 l/min, while with theTH, it is optimal at
60 l/min and below this level strongly dependent upon
the generated inspiratory £ow (8,12^14). Because in this
study all patients were stimulated to do their utmost
best, the results presented here probably overestimate
the number of patients generating an adequate £ow
whilst inhaling their medication. At home a larger per-
centage of patients will not inhale optimally. A previous
study showed that during a comfortable inhalation the
PIF values were considerably lower (20). For theTH, the
mean PIF decreased by 42%, while for the DK this was
44%. The consequence seems mainly relevant for the
TH, because patients will reach the critical 30 l/min
sooner thanwith theDK.Thismeans that probably a lar-
ger part of the patients will not inhale their medication
adequately, with all the detrimental consequences. In
conclusion, this pilot study showed that in choosing the
correct inhaler for a speci¢c patient, the inhaler resis-
tance and the required inspiratory £owmust play a role.
Mainly in patients who experience exacerbations, it is
important to checkwhether a patientwith a reduced in-
spiratory £ow can still inhale themedication adequately.
When in doubt about the necessary inspiratory force, a
simple assessment with the In-Check DIALs is advisa-
ble.
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